Role of CXCR2 Ligands/CXCR2 Biological Axis in Pancreatic Cancer

Completed

Conditions studied: Chronic Pancreatitis, Pancreatic Cancer

In brief

The investigators hypothesize that the CXCR2 ligands/CXCR2 biological axis plays an important role in promoting angiogenesis in PC; and that the genetic changes and the microenvironment of the tumor regulate the expression of CXCR2 ligands/CXCR2 in PC in order to potentiate their angiogenic phenotype. A corollary of this hypothesis is that the cell surface receptors (CXCR2) and the intracellular signaling pathways that mediate the angiogenic responses induced by ELR+ CXC-chemokines are potential targets for novel therapeutic interventions in PC.

Key facts

Study ID

NCT00851955

Run by

Mayo Clinic

People needed

150

Starts

2007-05-01

Expected to finish

2011-11-01

Last updated by the study team

2016-01-12

Who can join

Age: 18 and older, up to 90. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Normal subjects - No documented clinical history of pancreatic diseases supported by at least 1 negative imaging test. (EUS, Ct scan or MRI)
• Chronic pancreatitis - Documented diagnosis of moderate to advanced chronic supported bpancreatitisy at least 1 positive imaging test. (EUS, Ct scan or MRI)
• Pancreatic Cancer - Documented tissue diagnosis (or clinical suspicion) of Pancreatic Cancer.

You may not qualify if…

• Exclusion criteria will include age younger than 18 yrs, pregnancy, previous pancreatic or gastric resection, and inability to tolerate routine endoscopy with conscious sedation

Where it is running

• Mayo Clinic — Jacksonville, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.